|Bid||28.52 x 800|
|Ask||28.55 x 1000|
|Day's Range||28.52 - 29.50|
|52 Week Range||21.70 - 51.30|
|Beta (3Y Monthly)||2.52|
|PE Ratio (TTM)||179.06|
|Earnings Date||Oct 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.00|
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that Dr. Jorn S. Jorgensen successfully implanted the Company’s EVO Visian ICL in his son, Jannik Jorgensen, during a live-streamed event which also celebrated the opening of EuroEyes’ newest clinic. Dr. Jorgensen is the founder, chairman, executive director and CEO of the EuroEyes clinic group, with clinics across Germany, Denmark and China.
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended September 27, 2019 on Wednesday, October 30, 2019 after the market close. STAAR will host a conference call and webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 7170127), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants.
Today we'll look at STAAR Surgical Company (NASDAQ:STAA) and reflect on its potential as an investment. To be precise...
STAAR Surgical Company , a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing the EVO ICL Clinical Program which will be presented by Ophthalmic Surgeons to Ophthalmic Surgeons at its invitation only Surgical Experts Summit.
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it has entered a strategic alliance with Asian Eye Institute, an eye care group with nine locations in the Philippines. “‘Amazing’, ‘Wow’, ‘It’s so clear’, and ‘I am so happy’ are the words I often hear after performing the Visian® EVO ICL procedure and I am confident and proud to partner with STAAR in offering the EVO family of lenses to my patients,” said Dr. Robert “Bobby” Edward Ang, M.D., senior consultant and Head of Cornea and Refractive Surgery Services at Asian Eye Institute.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Staar Surgical (STAA) delivered earnings and revenue surprises of 40.00% and -1.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How far off is STAAR Surgical Company (NASDAQ:STAA) from its intrinsic value? Using the most recent financial data...
NEW YORK, NY / ACCESSWIRE / June 27, 2019 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (STAA). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. The investigation concerns whether STAAR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...